방사선 선량 관리 시장 : 기능별(선량 모니터링, 벤치마크, 보고, 방사선 관리), 기술별(AI), 도입 형태별, 모달리티별(CT, PET, SPECT), 용도별(암), 최종사용자별(병원) - 세계 예측(-2031년)

The radiation dose management market is projected to reach USD 0.96 billion by 2031 from USD 0.51 billion in 2026, at a CAGR of 13.3% from 2026 to 2031. The market is experiencing steady growth owing to the increasing utilization of medical imaging procedures, rising focus on patient radiation safety, regulatory emphasis on radiation dose monitoring and optimization, and growing adoption of automated dose management systems.

The increasing volume and complexity of imaging procedures are accelerating the use of RDM systems across hospitals, healthcare systems, diagnostic and imaging centers, and other imaging facilities. These systems enable healthcare organizations to collect, monitor, archive, analyze, and share patient radiation dose data; identify dose variations; compare radiation exposure across facilities and procedures; support diagnostic reference levels (DRLs); and optimize imaging practices.

"By offering, solutions accounted for the dominant share of the radiation dose management market in 2025."

Based on offering, the radiation dose management market is segmented into solutions and services. The solutions segment accounted for the dominant share of the market in 2025, driven by the increasing adoption of software platforms that automate radiation-dose data collection, monitoring, analysis, reporting, benchmarking, and optimization across medical imaging environments. RDM solutions enable healthcare organizations to collect and analyze dose information from multiple imaging modalities, identify dose variations and outliers, compare radiation exposure against diagnostic reference levels (DRLs), and support imaging-protocol optimization. The solutions segment is also benefiting from the shift from standalone dose-tracking tools toward integrated and interoperable dose-management platforms that connect imaging modalities with PACS, RIS, hospital information systems, and other healthcare IT infrastructure. The continued adoption of automated alerts, dose analytics, patient dose tracking, and advanced optimization capabilities is expected to support demand for RDM solutions throughout the forecast period.

"By deployment model, the cloud-based deployment is expected to witness high growth during the forecast period."

Based on deployment model, the radiation dose management market is segmented into on-premises and cloud-based/web-based deployment. The cloud-based/web-based deployment segment is expected to register higher CAGR during the forecast period, supported by the increasing need for centralized and remotely accessible dose-management systems across hospitals, diagnostic and imaging centers, and multi-site healthcare networks. Cloud-based and web-based RDM platforms allow healthcare organizations to access dose information across facilities, support centralized monitoring and benchmarking, and reduce the need for extensive on-site infrastructure. The adoption of these deployment models is further supported by the growing need to integrate dose data with PACS, RIS, and other healthcare information systems.

"North America accounted for the largest share of the radiation dose management market in 2025."

The radiation dose management market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest share of the market in 2025, supported by well-established healthcare infrastructure, high adoption of advanced medical imaging technologies, large imaging volumes, and increasing emphasis on radiation safety and dose optimization. The US and Canada have mature healthcare systems with widespread use of CT, fluoroscopy, and interventional imaging, radiography, mammography, and nuclear medicine, creating strong demand for technologies that monitor and manage radiation exposure. Healthcare organizations across the region are increasingly adopting RDM solutions to automate dose monitoring, identify dose variations, benchmark radiation exposure, and support imaging protocol optimization. The presence of established RDM providers and a mature healthcare IT ecosystem further supports adoption of dose management technologies across hospitals, healthcare systems, and diagnostic imaging facilities. The continued expansion of advanced imaging and growing focus on patient safety and efficient dose management are expected to sustain North America's leading position in the RDM market during the forecast period.

The breakdown of primary interview participants is as mentioned below:

• By Company Type: Tier 1 - 45%, Tier 2 - 35%, and Tier 3 - 20%
• By Designation: C-level Executives - 26%, Directors - 17%, and Others - 57%
• By Region: North America - 40%, Europe - 20%, Asia Pacific - 30%, Latin America- 6%, and Middle East - 4%

Bayer AG (Germany) and GE HealthCare (US) are among the key players in the radiation dose management market.

• The study includes an in-depth competitive analysis of these key players in the radiation dose management market, with their company profiles, recent developments, and key market strategies.

Research Coverage

The report analyzes the radiation dose management market. It aims to estimate the market size and future growth potential of various market segments based on offering, function, technology, deployment model, revenue model, modality, application, end user, and region. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to buy this report

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the radiation dose management market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights into the following pointers:

• Analysis of key drivers (increasing utilization and complexity of imaging procedures, increasing regulatory emphasis on dose monitoring, optimization, and reference levels, growing concerns regarding radiation exposure and dose optimization), restraints (high implementation, integration, and maintenance costs, shortage of skilled professionals for radiation dose management and optimization), opportunities (increasing adoption of AI-enabled radiation dose optimization, growing adoption of vendor-neutral and cloud-based dose management platforms, increasing focus on age-specific radiation dose optimization), and challenges (lack of standardized and interoperable dose data across modalities and systems, variability in dose benchmarks and imaging protocols across institutions) influencing the growth of the radiation dose management market
• Product Development/Innovation: Detailed insights into upcoming technologies, research & development activities, and new product & service launches in the radiation dose management market
• Market Development: Comprehensive information about lucrative markets (the report analyzes the radiation dose management market across varied regions)
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the radiation dose management market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players such as Bayer AG (Germany), GE HealthCare (US), Koninklijke Philips N.V. (Netherlands), Siemens Healthineers AG (Germany), Sectra AB (Sweden), and FUJIFILM Holdings Corporation (Japan)

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
• 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS SHAPING MARKET
• 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
• 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 RADIATION DOSE MANAGEMENT MARKET OVERVIEW
• 3.2 NORTH AMERICA: RADIATION DOSE MANAGEMENT MARKET, BY OFFERING AND COUNTRY
• 3.3 RADIATION DOSE MANAGEMENT MARKET: REGIONAL GROWTH OPPORTUNITIES

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Increasing utilization and complexity of imaging procedures
    • 4.2.1.2 Increasing regulatory emphasis on dose monitoring, optimization, and reference levels
    • 4.2.1.3 Growing concerns regarding radiation exposure and dose optimization
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 High implementation and integration costs
    • 4.2.2.2 Shortage of skilled professionals for radiation dose management and optimization
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 Increasing adoption of AI-enabled radiation dose optimization
    • 4.2.3.2 Growing adoption of vendor-neutral and cloud-based dose management platforms
    • 4.2.3.3 Increasing focus on age-specific radiation dose optimization
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Lack of standardized and interoperable dose data across modalities and systems
    • 4.2.4.2 Variability in dose benchmarks and imaging protocols across institutions
• 4.3 UNMET NEEDS AND WHITE SPACES
• 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 THREAT OF NEW ENTRANTS
  • 5.1.2 THREAT OF SUBSTITUTES
  • 5.1.3 BARGAINING POWER OF SUPPLIERS
  • 5.1.4 BARGAINING POWER OF BUYERS
  • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.2 MACROECONOMIC INDICATORS
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS AND FORECAST
  • 5.2.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY
• 5.3 VALUE CHAIN ANALYSIS
  • 5.3.1 RESEARCH & PRODUCT DEVELOPMENT
  • 5.3.2 DATA & KNOWLEDGE ASSETS
  • 5.3.3 SOFTWARE & PLATFORM INFRASTRUCTURE
  • 5.3.4 CLOUD SERVICE PROVIDERS
  • 5.3.5 MARKETING & SALES
  • 5.3.6 POST-SALES SERVICES
• 5.4 ECOSYSTEM ANALYSIS
• 5.5 PRICING ANALYSIS
  • 5.5.1 INDICATIVE PRICE FOR RADIATION DOSE MANAGEMENT MARKET, BY PRODUCT (2025)
  • 5.5.2 INDICATIVE PRICE FOR RADIATION DOSE MANAGEMENT MARKET, BY REGION (2025)
• 5.6 KEY CONFERENCES AND EVENTS
• 5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.8 INVESTMENT AND FUNDING SCENARIO
• 5.9 CASE STUDY ANALYSIS
  • 5.9.1 REDUCING CT DOSE THROUGH REAL-TIME DOSE MONITORING AND ALERTING
  • 5.9.2 ESTABLISHING ENTERPRISE-WIDE, MULTI-MODALITY DOSE MANAGEMENT
  • 5.9.3 REDUCED RADIATION DOSE IN SPECIALIST CANCER CARE
  • 5.9.4 IMPROVED CARE COORDINATION
• 5.10 IMPACT OF US TARIFF OVERVIEW
  • 5.10.1 INTRODUCTION
  • 5.10.2 KEY TARIFF RATES
• 5.11 PRICE IMPACT ANALYSIS
• 5.12 IMPACT ON COUNTRY/REGION
  • 5.12.1 US
  • 5.12.2 EUROPE
  • 5.12.3 ASIA PACIFIC
• 5.13 IMPACT ON END USERS
  • 5.13.1 HOSPITALS AND HEALTHCARE SYSTEMS
  • 5.13.2 DIAGNOSTIC AND IMAGING CENTERS
  • 5.13.3 AMBULATORY SURGERY CENTERS
  • 5.13.4 OTHER END USERS

6 STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, DIGITAL, AND AI ADOPTION

• 6.1 KEY EMERGING TECHNOLOGIES
  • 6.1.1 AI-ENABLED RADIATION DOSE PREDICTION, MONITORING, AND OPTIMIZATION
  • 6.1.2 PATIENT-SPECIFIC AND PERSONALIZED DOSIMETRY TECHNOLOGIES
  • 6.1.3 ADVANCED IMAGING TECHNOLOGIES FOR RADIATION DOSE OPTIMIZATION
• 6.2 COMPLEMENTARY TECHNOLOGIES
  • 6.2.1 DICOM, RADIATION DOSE STRUCTURED REPORTS (RDSR), AND INTEROPERABILITY TECHNOLOGIES
  • 6.2.2 CLOUD-BASED, VENDOR-NEUTRAL, AND ENTERPRISE DOSE MANAGEMENT ARCHITECTURES
  • 6.2.3 DOSE REGISTRIES, BENCHMARKING, AND POPULATION-LEVEL DOSE ANALYTICS
• 6.3 ADJACENT TECHNOLOGIES
  • 6.3.1 COMPUTATIONAL DOSIMETRY AND PATIENT-SPECIFIC DOSE MODELING
• 6.4 TECHNOLOGY/PRODUCT ROADMAP
• 6.5 PATENT ANALYSIS
  • 6.5.1 PATENT PUBLICATION TRENDS FOR RADIATION DOSE MANAGEMENT
  • 6.5.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
• 6.6 FUTURE APPLICATIONS
  • 6.6.1 AI-ASSISTED PERSONALIZED RADIATION DOSE MANAGEMENT
  • 6.6.2 REAL-TIME DOSE OPTIMIZATION AND INTELLIGENT IMAGING WORKFLOW AUTOMATION
  • 6.6.3 LONGITUDINAL RADIATION-EXPOSURE MANAGEMENT AND PREDICTIVE DOSE ANALYTICS
• 6.7 IMPACT OF AI/GEN AI ON RADIATION DOSE MANAGEMENT MARKET
  • 6.7.1 INTRODUCTION
  • 6.7.2 POTENTIAL OF AI/GEN AI IN RADIATION DOSE MANAGEMENT MARKET
  • 6.7.3 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION
  • 6.7.4 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
  • 6.7.5 MEDICAL IMAGING EQUIPMENT & IMAGING INFORMATICS
  • 6.7.6 DOSE REGISTRIES, BENCHMARKING & QUALITY MANAGEMENT
  • 6.7.7 AI-ENABLED IMAGING & CLINICAL WORKFLOW
  • 6.7.8 USER READINESS AND IMPACT ASSESSMENT
    • 6.7.8.1 User readiness
      • 6.7.8.1.1 User A: Hospitals & integrated health systems
      • 6.7.8.1.2 User B: Practices outpatient diagnostic imaging centers & radiology practices
      • 6.7.8.1.3 User C: Interventional radiology & cardiology centers
    • 6.7.8.2 Impact assessment
      • 6.7.8.2.1 User A: Hospitals & integrated health systems
        • 6.7.8.2.1.1 Implementation
        • 6.7.8.2.1.2 Impact
      • 6.7.8.2.2 User B: Outpatient diagnostic imaging centers & radiology practices
        • 6.7.8.2.2.1 Implementation
        • 6.7.8.2.2.2 Impact
      • 6.7.8.2.3 User C: Interventional radiology & cardiology centers
        • 6.7.8.2.3.1 Implementation
        • 6.7.8.2.3.2 Impact

7 REGULATORY LANDSCAPE

• 7.1 REGIONAL REGULATIONS AND COMPLIANCE
  • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.1.2 REGULATORY FRAMEWORK
    • 7.1.2.1 North America
    • 7.1.2.2 Europe
    • 7.1.2.3 Asia Pacific
    • 7.1.2.4 Latin America
    • 7.1.2.5 Middle East & Africa
  • 7.1.3 INDUSTRY STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 8.1 INTRODUCTION
• 8.2 DECISION-MAKING PROCESS
• 8.3 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
• 8.4 KEY STAKEHOLDERS IN BUYING PROCESS
  • 8.4.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 8.4.2 BUYING CRITERIA
• 8.5 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 8.6 UNMET NEEDS FROM VARIOUS END USERS
  • 8.6.1 UNMET NEEDS
  • 8.6.2 END USER EXPECTATIONS
• 8.7 MARKET PROFITABILITY

9 RADIATION DOSE MANAGEMENT MARKET, BY OFFERING

• 9.1 INTRODUCTION
• 9.2 SOLUTIONS
  • 9.2.1 GROWING ADOPTION OF INTEGRATED AND AUTOMATED RADIATION DOSE MANAGEMENT SOLUTIONS TO DRIVE MARKET
  • 9.2.2 STANDALONE SOLUTIONS
    • 9.2.2.1 Growing demand for flexible and cost-effective dose monitoring solutions to boost market
  • 9.2.3 INTEGRATED SOLUTIONS
    • 9.2.3.1 Growing need for enterprise-wide, multi-vendor dose management to propel market
• 9.3 SERVICES
  • 9.3.1 GROWING NEED FOR SPECIALIZED IMPLEMENTATION, CONSULTING, AND TRAINING EXPERTISE TO BOOST MARKET
  • 9.3.2 SUPPORT & MAINTENANCE SERVICES
    • 9.3.2.1 Growing need for continuous system availability and software updates to boost market
  • 9.3.3 IMPLEMENTATION & INTEGRATION SERVICES
    • 9.3.3.1 Growing hospital networks to drive demand for implementation and integration services
  • 9.3.4 CONSULTING SERVICES
    • 9.3.4.1 Growing need to interpret dose trends and identify outliers to drive segment
  • 9.3.5 EDUCATION & TRAINING SERVICES
    • 9.3.5.1 Increasing need for skilled personnel to support radiation dose optimization to boost segment

10 RADIATION DOSE MANAGEMENT MARKET, BY FUNCTION

• 10.1 INTRODUCTION
• 10.2 DOSE TRACKING & MONITORING
  • 10.2.1 INCREASING ADOPTION OF AUTOMATED AND CONTINUOUS DOSE MONITORING
• 10.3 DOSE ANALYTICS & BENCHMARKING
  • 10.3.1 GROWING NEED TO IDENTIFY DOSE OUTLIERS AND BENCHMARK IMAGING PERFORMANCE BOOSTS SEGMENT
• 10.4 DOSE REPORTING & REGULATORY COMPLIANCE
  • 10.4.1 INCREASING REGULATORY EMPHASIS ON RADIATION DOSE DOCUMENTATION TO PROPEL SEGMENT
• 10.5 PROTOCOL & DOSE OPTIMIZATION
  • 10.5.1 SEGMENT DRIVEN BY INCREASING FOCUS ON DOSE REDUCTION WHILE MAINTAINING DIAGNOSTIC IMAGE QUALITY
• 10.6 PATIENT RADIATION EXPOSURE MANAGEMENT
  • 10.6.1 GROWING FOCUS ON PATIENT-SPECIFIC AND CUMULATIVE RADIATION EXPOSURE - KEY DRIVER
• 10.7 OTHER FUNCTIONS
  • 10.7.1 INCREASING NEED FOR INTEROPERABILITY ACROSS HETEROGENEOUS IMAGING ENVIRONMENTS TO DRIVE SEGMENT

11 RADIATION DOSE MANAGEMENT MARKET, BY TECHNOLOGY

• 11.1 INTRODUCTION
• 11.2 AI-ENABLED TECHNOLOGY
  • 11.2.1 GROWING ADOPTION OF AI DRIVES SEGMENT GROWTH
  • 11.2.2 MACHINE LEARNING
    • 11.2.2.1 Growing adoption of predictive and patient-specific dose optimization to boost segment
  • 11.2.3 DEEP LEARNING
    • 11.2.3.1 Increasing use of deep learning for automated imaging and dose optimization
  • 11.2.4 COMPUTER VISION
    • 11.2.4.1 Increasing automation of image analysis and anatomical assessment to drive segment
  • 11.2.5 NATURAL LANGUAGE PROCESSING (NLP)
    • 11.2.5.1 Increasing availability of unstructured clinical data - key driver
• 11.3 NON-AI/CONVENTIONAL TECHNOLOGY
  • 11.3.1 ESTABLISHED CLINICAL ADOPTION AND REGULATORY RELIABILITY

12 RADIATION DOSE MANAGEMENT MARKET, BY DEPLOYMENT MODEL

• 12.1 INTRODUCTION
• 12.2 ON-PREMISE DEPLOYMENT
  • 12.2.1 STRINGENT DATA-SECURITY POLICIES DRIVES SEGMENT GROWTH
• 12.3 CLOUD-BASED/WEB-BASED DEPLOYMENT
  • 12.3.1 INCREASING NEED FOR SCALABLE, MULTI-SITE DOSE MONITORING AND REMOTE ACCESS TO IMAGING ANALYTICS BOOSTS DEMAND

13 RADIATION DOSE MANAGEMENT MARKET, BY REVENUE MODEL

• 13.1 INTRODUCTION
• 13.2 CAPITAL/ANNUAL PURCHASE MODEL
  • 13.2.1 ESTABLISHED PROCUREMENT PRACTICES DRIVE DEMAND
• 13.3 PAY-PER-PROCEDURE MODEL
  • 13.3.1 AFFORDABILITY DRIVES SEGMENT GROWTH

14 RADIATION DOSE MANAGEMENT MARKET, BY MODALITY

• 14.1 INTRODUCTION
• 14.2 COMPUTED TOMOGRAPHY (CT)
  • 14.2.1 RAPID ADOPTION OF PHOTON-COUNTING CT AND AI-BASED RECONSTRUCTION TO DRIVE SEGMENT
• 14.3 FLUOROSCOPY & INTERVENTIONAL IMAGING
  • 14.3.1 RISING PROCEDURAL COMPLEXITY INCREASES DEMAND FOR REAL-TIME RADIATION DOSE REDUCTION
• 14.4 RADIOGRAPHY
  • 14.4.1 DIGITAL RADIOGRAPHY AND AI-BASED IMAGE ENHANCEMENT ENABLE LOWER EXPOSURE
• 14.5 MAMMOGRAPHY
  • 14.5.1 EXPANSION OF 3D BREAST IMAGING DRIVES DEMAND
• 14.6 NUCLEAR MEDICINE
  • 14.6.1 INCREASING USE OF HIGH-SENSITIVITY PET/SPECT AND AI-ENABLED RECONSTRUCTION TO DRIVE SEGMENT
  • 14.6.2 PET
    • 14.6.2.1 Higher PET sensitivity and AI reconstruction to boost demand
  • 14.6.3 SPECT
    • 14.6.3.1 Low-dose SPECT/CT technologies strengthen radiation optimization
  • 14.6.4 HYBRID
    • 14.6.4.1 Growing reliance on PET/CT and SPECT/CT drives market

15 RADIATION DOSE MANAGEMENT MARKET, BY APPLICATION

• 15.1 INTRODUCTION
• 15.2 ONCOLOGY
  • 15.2.1 INCREASING FOCUS ON ONCOLOGY DRIVES DEMAND
• 15.3 CARDIOLOGY
  • 15.3.1 INCREASING USE IN CARDIOLOGY BOOSTS DEMAND
• 15.4 ORTHOPEDIC
  • 15.4.1 HIGH COMPLEXITY OF PROCEDURES DRIVES DEMAND
• 15.5 DENTAL
  • 15.5.1 GROWING USE OF CBCT PROPELS DEMAND
• 15.6 OTHER APPLICATIONS
  • 15.6.1 NEED TO MANAGE REPEATED EXAMINATIONS DRIVES DEMAND

16 RADIATION DOSE MANAGEMENT MARKET, BY END USER

• 16.1 INTRODUCTION
• 16.2 HOSPITALS & HEALTHCARE SYSTEMS
  • 16.2.1 DIVERSE IMAGING FLEETS DRIVE CENTRALIZED RDM AND PROTOCOL OPTIMIZATION ACROSS HOSPITAL NETWORKS
• 16.3 DIAGNOSTIC & IMAGING CENTERS
  • 16.3.1 HIGH EXAMINATION VOLUMES AND MULTI-SITE IMAGING OPERATIONS ACCELERATE DEMAND
• 16.4 AMBULATORY CARE SETTINGS
  • 16.4.1 EXPANSION OF OUTPATIENT AND AMBULATORY IMAGING INCREASES DEMAND
• 16.5 ACADEMIC & RESEARCH INSTITUTES
  • 16.5.1 SEGMENT DRIVEN BY AI-DRIVEN LOW-DOSE IMAGING AND NEXT-GENERATION DOSE OPTIMIZATION TECHNOLOGIES
• 16.6 OTHER END USERS
  • 16.6.1 REGULATORY OVERSIGHT, POPULATION-LEVEL RADIATION MONITORING, AND CLINICAL-TRIAL - KEY DRIVERS

17 RADIATION DOSE MANAGEMENT MARKET, BY REGION

• 17.1 INTRODUCTION
• 17.2 NORTH AMERICA
  • 17.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 17.2.2 US
    • 17.2.2.1 Regulatory focus on radiation safety drives market
  • 17.2.3 CANADA
    • 17.2.3.1 Increasing number of diagnostic imaging procedures to boost market
• 17.3 EUROPE
  • 17.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 17.3.2 GERMANY
    • 17.3.2.1 Rising diagnostic imaging demand and aging population to drive market
  • 17.3.3 FRANCE
    • 17.3.3.1 Healthcare modernization to accelerate radiation dose management adoption
  • 17.3.4 UK
    • 17.3.4.1 Rising imaging volumes and NHS digitalization to support market growth
  • 17.3.5 ITALY
    • 17.3.5.1 Regulatory emphasis on dose optimization and monitoring to propel market
  • 17.3.6 SPAIN
    • 17.3.6.1 Growing focus on patient dosimetry and radiation dose optimization to drive market
  • 17.3.7 REST OF EUROPE
• 17.4 ASIA PACIFIC
  • 17.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 17.4.2 CHINA
    • 17.4.2.1 Largest patient pool and increased healthcare spending to aid market growth
  • 17.4.3 JAPAN
    • 17.4.3.1 Large and technologically advanced hospital infrastructure
  • 17.4.4 INDIA
    • 17.4.4.1 Favorable government policies and improved healthcare infrastructure to support market growth
  • 17.4.5 AUSTRALIA
    • 17.4.5.1 Advancement of national diagnostic reference levels to accelerate radiation dose optimization
  • 17.4.6 SOUTH KOREA
    • 17.4.6.1 Increasing medical imaging volumes and patient radiation exposure to boost market
  • 17.4.7 REST OF ASIA PACIFIC
• 17.5 LATIN AMERICA
  • 17.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 17.5.2 BRAZIL
    • 17.5.2.1 Increasing regulatory focus and adoption of advanced imaging technologies to drive market
  • 17.5.3 MEXICO
    • 17.5.3.1 Rising demand for diagnostic imaging and adoption of lower-dose technologies to support market growth
  • 17.5.4 REST OF LATIN AMERICA
• 17.6 MIDDLE EAST & AFRICA
  • 17.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 17.6.2 GCC COUNTRIES
    • 17.6.2.1 Saudi Arabia
      • 17.6.2.1.1 Growing healthcare expenditure to boost market growth
    • 17.6.2.2 UAE
      • 17.6.2.2.1 Increasing healthcare infrastructure investments to drive market growth
    • 17.6.2.3 Rest of GCC
  • 17.6.3 SOUTH AFRICA
    • 17.6.3.1 Increasing focus on radiation dose optimization to propel market growth
  • 17.6.4 REST OF MIDDLE EAST & AFRICA

18 COMPETITIVE LANDSCAPE

• 18.1 OVERVIEW
• 18.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023-2026
• 18.3 REVENUE ANALYSIS, 2021-2025
• 18.4 MARKET SHARE ANALYSIS, 2021-2025
• 18.5 BRAND COMPARISON
• 18.6 COMPANY VALUATION AND FINANCIAL METRICS
• 18.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
  • 18.7.1 STARS
  • 18.7.2 EMERGING LEADERS
  • 18.7.3 PERVASIVE PLAYERS
  • 18.7.4 PARTICIPANTS
  • 18.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
    • 18.7.5.1 Company footprint
    • 18.7.5.2 Region footprint
    • 18.7.5.3 Offering footprint
    • 18.7.5.4 Deployment model footprint
    • 18.7.5.5 Technology footprint
• 18.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
  • 18.8.1 PROGRESSIVE COMPANIES
  • 18.8.2 RESPONSIVE COMPANIES
  • 18.8.3 DYNAMIC COMPANIES
  • 18.8.4 STARTING BLOCKS
  • 18.8.5 COMPETITIVE BENCHMARKING STARTUPS/SMES, 2025
• 18.9 COMPETITIVE SCENARIO
  • 18.9.1 DEALS
  • 18.9.2 OTHER DEVELOPMENTS

19 COMPANY PROFILES

• 19.1 KEY PLAYERS
  • 19.1.1 BAYER AG
    • 19.1.1.1 Products/solutions/services offered
    • 19.1.1.2 Recent developments
      • 19.1.1.2.1 Product launches & upgrades
      • 19.1.1.2.2 Deals
      • 19.1.1.2.3 Other developments
    • 19.1.1.3 MnM view
      • 19.1.1.3.1 Key strengths
      • 19.1.1.3.2 Strategic choices
      • 19.1.1.3.3 Weaknesses and competitive threats
  • 19.1.2 SIEMENS HEALTHINEERS AG
    • 19.1.2.1 Business overview
    • 19.1.2.2 Products/solutions/services offered
    • 19.1.2.3 Recent developments
      • 19.1.2.3.1 Product launches & upgrades
      • 19.1.2.3.2 Deals
      • 19.1.2.3.3 Expansions
    • 19.1.2.4 MnM view
      • 19.1.2.4.1 Key strengths
      • 19.1.2.4.2 Strategic choices
      • 19.1.2.4.3 Weaknesses and competitive threats
  • 19.1.3 KONINKLIJKE PHILIPS N.V.
    • 19.1.3.1 Business overview
    • 19.1.3.2 Products/solutions/services offered
    • 19.1.3.3 Recent developments
      • 19.1.3.3.1 Product launches & upgrades
      • 19.1.3.3.2 Deals
    • 19.1.3.4 MnM view
      • 19.1.3.4.1 Key strengths
      • 19.1.3.4.2 Strategic choices
      • 19.1.3.4.3 Weaknesses and competitive threats
  • 19.1.4 GE HEALTHCARE
    • 19.1.4.1 Business overview
    • 19.1.4.2 Products/solutions/services offered
    • 19.1.4.3 Recent developments
      • 19.1.4.3.1 Product launches & upgrades
      • 19.1.4.3.2 Deals
      • 19.1.4.3.3 Other developments
    • 19.1.4.4 MnM view
      • 19.1.4.4.1 Key strengths
      • 19.1.4.4.2 Strategic choices
      • 19.1.4.4.3 Weaknesses and competitive threats
  • 19.1.5 FUJIFILM HOLDINGS CORPORATION
    • 19.1.5.1 Business overview
    • 19.1.5.2 Products/solutions/services offered
    • 19.1.5.3 Recent developments
      • 19.1.5.3.1 Product launches & upgrades
      • 19.1.5.3.2 Deals
      • 19.1.5.3.3 Other developments
    • 19.1.5.4 MnM view
      • 19.1.5.4.1 Key strengths
      • 19.1.5.4.2 Strategic choices
      • 19.1.5.4.3 Weaknesses and competitive threats
  • 19.1.6 SECTRA AB
    • 19.1.6.1 Business overview
    • 19.1.6.2 Products/solutions/services offered
    • 19.1.6.3 Recent developments
      • 19.1.6.3.1 Product launches & upgrades
      • 19.1.6.3.2 Deals
      • 19.1.6.3.3 Other developments
  • 19.1.7 CANON INC.
    • 19.1.7.1 Business overview
    • 19.1.7.2 Products/solutions/services offered
    • 19.1.7.3 Recent developments
      • 19.1.7.3.1 Product launches & upgrades
      • 19.1.7.3.2 Deals
      • 19.1.7.3.3 Other developments
  • 19.1.8 AGFA-GEVAERT N.V.
    • 19.1.8.1 Business overview
    • 19.1.8.2 Products/solutions/services offered
    • 19.1.8.3 Recent developments
      • 19.1.8.3.1 Product launches & upgrades
      • 19.1.8.3.2 Deals
  • 19.1.9 PACSHEALTH, LLC
    • 19.1.9.1 Business overview
    • 19.1.9.2 Products/solutions/services offered
    • 19.1.9.3 Recent developments
      • 19.1.9.3.1 Deals
  • 19.1.10 QAELUM
    • 19.1.10.1 Business overview
    • 19.1.10.2 Products/solutions/services offered
    • 19.1.10.3 Recent developments
      • 19.1.10.3.1 Deals
  • 19.1.11 MEDSQUARE
    • 19.1.11.1 Business overview
    • 19.1.11.2 Products/solutions/services offered
    • 19.1.11.3 Recent developments
      • 19.1.11.3.1 Product launches & upgrades
      • 19.1.11.3.2 Deals
  • 19.1.12 NOVARAD
    • 19.1.12.1 Business overview
    • 19.1.12.2 Products/solutions/services offered
  • 19.1.13 INFINITT HEALTHCARE CO., LTD.
    • 19.1.13.1 Business overview
    • 19.1.13.2 Products/solutions/services offered
  • 19.1.14 CARESTREAM HEALTH
    • 19.1.14.1 Business overview
    • 19.1.14.2 Products/solutions/services offered
    • 19.1.14.3 Recent developments
      • 19.1.14.3.1 Product Launches & upgrades
      • 19.1.14.3.2 Deals
  • 19.1.15 SHIMADZU CORPORATION
    • 19.1.15.1 Business overview
    • 19.1.15.2 Products/solutions/services offered
    • 19.1.15.3 Recent developments
      • 19.1.15.3.1 Products launches & upgrades
      • 19.1.15.3.2 Deals
  • 19.1.16 NANJING PERLOVE MEDICAL EQUIPMENT CO., LTD.
    • 19.1.16.1 Business overview
    • 19.1.16.2 Products/solutions/services offered
    • 19.1.16.3 Recent developments
      • 19.1.16.3.1 Product Launches & upgrades
      • 19.1.16.3.2 Deals
  • 19.1.17 NEUSOFT MEDICAL SYSTEMS CO., LTD.
    • 19.1.17.1 Business overview
    • 19.1.17.2 Products/solutions/services offered
    • 19.1.17.3 Recent developments
      • 19.1.17.3.1 Product launches & upgrades
      • 19.1.17.3.2 Deals
  • 19.1.18 KONICA MINOLTA, INC
    • 19.1.18.1 Business overview
    • 19.1.18.2 Products/solutions/services offered
    • 19.1.18.3 Recent developments
      • 19.1.18.3.1 Product Launches & upgrades
      • 19.1.18.3.2 Deals
  • 19.1.19 IBA
    • 19.1.19.1 Business overview
    • 19.1.19.2 Products/solutions/services offered
    • 19.1.19.3 Recent developments
      • 19.1.19.3.1 Product launches & upgrades
      • 19.1.19.3.2 Deals
  • 19.1.20 LUNIT INC.
    • 19.1.20.1 Business overview
    • 19.1.20.2 Products/solutions/services offered
    • 19.1.20.3 Recent developments
      • 19.1.20.3.1 Deals
• 19.2 OTHER PLAYERS
  • 19.2.1 QIT SYSTEME GMBH
  • 19.2.2 IMALOGIX
  • 19.2.3 IDOSE
  • 19.2.4 MYXRAYDOSE LTD.
  • 19.2.5 VIRTUAL PHANTOMS INC.

20 RESEARCH METHODOLOGY

• 20.1 RESEARCH APPROACH
  • 20.1.1 SECONDARY RESEARCH
    • 20.1.1.1 Key data from secondary sources
  • 20.1.2 PRIMARY RESEARCH
    • 20.1.2.1 Key data from primary sources
    • 20.1.2.2 Insights from primary experts
• 20.2 RESEARCH METHODOLOGY
• 20.3 MARKET SIZE ESTIMATION
• 20.4 MARKET BREAKDOWN DATA TRIANGULATION
• 20.5 MARKET SHARE ESTIMATION
• 20.6 STUDY ASSUMPTIONS
• 20.7 LIMITATIONS
  • 20.7.1 SCOPE-RELATED LIMITATIONS
  • 20.7.2 METHODOLOGY-RELATED LIMITATIONS
• 20.8 RISK ASSESSMENT

21 APPENDIX

• 21.1 DISCUSSION GUIDE
• 21.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 21.3 CUSTOMIZATION OPTIONS
• 21.4 RELATED REPORTS
• 21.5 AUTHOR DETAILS